Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Saeed K Alzghari"'
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 40:239-255
The rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) now includes two agents, pembrolizumab and atezolizumab, approved for first-line treatment of advanced non-small cell lung cancer (aNSCLC) as monotherapy or as part of chemoimmun
Autor:
Saeed K. Alzghari, Kerry Anne Rambaran
Publikováno v:
The Ochsner Journal
Background: Thrombosis, well known as a condition of the elderly, is occurring in the otherwise healthy adolescent population. Immobility is a significant risk factor for venous thromboembolism (VTE), and adolescents who play video games are immobile
Autor:
Alexander D. Le, Saeed K Alzghari
Publikováno v:
Interdisciplinary Toxicology, Vol 12, Iss 2, Pp 83-88 (2019)
Interdisciplinary Toxicology
Interdisciplinary Toxicology
Butyrfentanyl and its analogues are being increasingly used throughout the United States and Europe. Currently, lethal cases are emerging across the United States, England, and Europe without any end in sight. We therefore performed a systematic revi
Autor:
Saeed K Alzghari, Valerie S. Acuña
Publikováno v:
Journal of Clinical Virology
In December of 2019, an outbreak of inexplicable pneumonia cases in several patients appeared in Wuhan, China. What is now known as coronavirus disease 2019 (COVID-19) has spread widely since then and, as of this writing, has infected over 1.8 millio
Publikováno v:
Cureus
As the opioid crisis in the United States continues to grow, non-fentanyl-derived synthetic opioids (NSOs) are growing in both availability and popularity. NSO use comes with considerable risk including a high potential for both abuse and overdose. I
Publikováno v:
Baylor University Medical Center Proceedings. 31:303-306
AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, a
Autor:
Young R. Lee, Delilah D. Blanco, Jackson D. Hager, Kailey S. Kuntz, Pamela D. Miller, Saeed K Alzghari
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:155-170
Critically ill patients display altered pharmacokinetics and pharmacodynamics and are more likely to be infected with more resistant pathogens. Beta-lactam antibiotics exhibit time-dependent pharmacodynamics; therefore, it is postulated that continuo
Autor:
Saeed K Alzghari, Stefania Koutsilieri, Kelly E. Caudle, George P. Patrinos, Mary V. Relling, Andrew A. Monte
Publikováno v:
American Journal of Hematology.
Autor:
Saeed K Alzghari, Kerry Anne Rambaran
Multiple medications are used in cardiac patient care including various inotropic and dysrhythmic drugs. However, these agents are not without adverse effects. In this chapter, we provide a brief review of case reports of adverse events and note-wort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfda81faaffa6ce7f1bacab24728c27b
https://doi.org/10.1016/bs.seda.2019.06.002
https://doi.org/10.1016/bs.seda.2019.06.002
Publikováno v:
Journal of Controlled Release. 232:255-264
While liposome-mediated delivery of cytotoxic chemotherapy has been shown to significantly enhance drug tolerability in patients as compared to the conventional formulation, the fundamental question remains whether they also improve anticancer effica